Kineta to Present Anti-CD27 Agonist Preclinical Program at AACR Conference on Tumor Immunology and Immunotherapy
Seattle, WA – (October 12, 2022) Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today that ...